Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data

 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment.

Highlights:

• GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.

• The study results provide further clinical validation for the breast cancer risk score component of recently announced Comprehensive Breast and Ovarian HBOC Risk Test.

• The study highlighted geneType’s ability, when using United States clinical guidelines,1 to identify more women for whom chemoprevention or increased screening would improve outcomes.

• GeneType and the more complex Rosner model had similar performance, with geneType’s data collection simplicity making its adoption in general practice easier.

• If women with stage 2 and above breast cancer had been assessed with geneType they could have been diagnosed with earlier stage cancer, with the corresponding prognostic improvements.

• The use of geneType could improve uptake of risk-reducing medication, potentially resulting in a significant reduction in the incidence of breast cancer.

https://finance.yahoo.com/news/publication-highlights-genetype-ability-detect-130000460.html